Monday, December 16, 2019

HemaCare Acquired For $380M

Northridge-based HemaCare, which develops products for the cell therapy market, has been acquired by Charles River Laboratories International, in a deal worth $380M in cash, the companies announced early this morning. HemaCare develops human-derived cellular products for cell therapy, providing a wide range of human primary cell types, plus cell processing services to support the discovery, development, and manufacture of cell therapies. Charles River said the acquisition will help it expand its scientific capabilities in the emerging, high-growth cell therapy sector. More information »